|
LIVE WEBINAR: Wednesday, April 19, 2023, 5:00 PM – 6:00 PM Eastern Time (ET)
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Oncology A Multitumor CME/MOC-Accredited Live Webinar Series
Join us on Wednesday, April 19th for this CME/MOC-accredited webinar Faculty
Pashtoon M Kasi, MD, MS Director, Colon Cancer Research Director, Liquid Biopsy Research Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine Englander Institute for Precision Medicine Division of Hematology and Medical Oncology NewYork-Presbyterian Hospital/Weill Cornell Medicine New York, New York
Wells A Messersmith, MD
Chief Medical Officer, Oncology Services Professor and Head, Division of Medical Oncology University of Colorado Cancer Center Aurora, Colorado Moderator Neil Love, MD Research To Practice Miami, Florida Wednesday, April 19, 2023 Topics to Be Discussed
Target Audience Learning Objectives
CE Credit Accreditation Statement Credit Designation Statement American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC) Content Validation and Disclosures FACULTY — The following faculty reported relevant financial relationships with ineligible entities: Dr Kasi — Consulting Agreements: AstraZeneca Pharmaceuticals LP, BostonGene, Daiichi Sankyo Inc, Delcath Systems Inc, DoMore Diagnostics, Eisai Inc, Exact Sciences Corporation, Foundation Medicine, Illumina, Incyte Corporation, Lilly, Merck Sharp & Dohme LLC, Natera Inc, NeoGenomics, QED Therapeutics, SAGA Diagnostics AB, Seagen Inc, Servier Pharmaceuticals LLC, Taiho Oncology Inc, Tempus; Scientific Advisory Board Member: Elicio Therapeutics; Stock Options/Ownership — Public Company: Elicio Therapeutics (Angion Biomedica Corp). Dr Messersmith — Consulting Agreements: Cardiff Oncology, Istari Oncology; Contracted Research: ALX Oncology, AStar EDDC, BeiGene Ltd, CanBas Co Ltd, Exelixis Inc, Fate Therapeutics, Pfizer Inc, PureTech Health, Mirati Therapeutics Inc, Rascal Therapeutics; Data and Safety Monitoring Board/Committee: Amgen Inc, QED Therapeutics, Zymeworks Inc; Unpaid Advisory Board: Pfizer Inc, Takeda Pharmaceuticals USA Inc; Nonrelevant Financial Relationship: Criterium. MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc. RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS Supporters |